ARAF as a New Driver in Lung Adenocarcinoma

Luiz H. Araujo, MD, medical oncologist, Corporate Cancer Foundation fellow, Ohio State’s Comprehensive Cancer Center — James Cancer Hospital and Solove Research Institute, discusses the discovery of oncogenicARAFas a new driver for lung cancer.

Clinical Pearls:

• When a 66-year-old lung cancer patient responded to sorafenib, her tumor and normal tissue was taken for sequencing.
• Researchers found a new mutation called ARAF.
• When ARAF is placed in cell lines, the cell lines develop tumors.
• It was found that sorafenib can reverse the phenotype.